Keyphrases
5-fluorouracil (5-FU)
5%
Adjuvant Immunotherapy
50%
Adjuvant Therapy
25%
Adverse Effects
5%
After Surgery
5%
Anti-PD-1
37%
Attention Function
11%
Attention Memory
5%
Brain Metastases
12%
Breast Cancer
50%
Chemotherapy
50%
Chemotherapy-related Cognitive Impairment
5%
Clinical Characteristics
12%
Clinical Trials
25%
Cognitive Impairment
50%
Cognitive Performance
5%
Cyclophosphamide
5%
Dabrafenib
50%
Demographic Characteristics
12%
Divided Attention
5%
Early Relapse
12%
Epirubicin
5%
Executive Attention
5%
Executive Function
16%
Immune-related Adverse Events
12%
Improved Outcomes
12%
Late Relapse
12%
Longitudinal Change
5%
Melanoma
37%
Melanoma Patients
12%
Melanoma Survival
50%
Memory Fluency
5%
Memory Function
5%
Memory-guided Attention
5%
Multicenter Observational Study
12%
Number of Metastatic Sites
12%
Post-chemotherapy
5%
Practice Effects
50%
Primary Melanoma
12%
Prognostic Factors
50%
Prognostic Patterns
50%
Real-world Outcomes
12%
Recurrence-free Survival
37%
Relapse Pattern
50%
Repeated Assessment
5%
Resection
25%
Survival Outcomes
50%
Taxanes
5%
Time to Discontinuation
16%
Women with Breast Cancer
11%
Medicine and Dentistry
Adjuvant Therapy
46%
Adverse Event
30%
Asthenia
10%
Brain Metastasis
8%
Clinical Trial
16%
Dabrafenib
50%
Diarrhea
10%
Disease Exacerbation
20%
Fever
10%
Immune-Related Adverse Events
8%
Immunotherapy
50%
MEK Inhibitor
10%
Melanoma
100%
Observational Study
58%
Overall Survival
10%
Prognostic Factor
50%
Recurrence Free Survival
34%
Recurrent Disease
16%
Survival Rate
18%
Time to Treatment
10%
Trametinib
50%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
30%
Asthenia
10%
Dabrafenib
50%
Diarrhea
10%
Disease Exacerbation
20%
Fever
10%
Melanoma
50%
Mitogen Activated Protein Kinase Kinase Inhibitor
10%
Observational Study
50%
Overall Survival
10%
Recurrence Free Survival
10%
Survival Rate
10%
Trametinib
50%
